+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ophthalmic Disease Therapeutics Market Report and Forecast 2024-2032

  • PDF Icon


  • 200 Pages
  • September 2023
  • Region: Global
  • Expert Market Research
  • ID: 5895170
The ophthalmic disease therapeutics market value was USD 35.7 billion in 2023, driven by the increasing prevalence of eye diseases across the globe. The market size is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to achieve a value of USD 62.5 billion by 2032.

Ophthalmic Disease Therapeutics: Introduction

Ophthalmic disease therapeutics refer to the various treatments and medications used to manage and treat diseases and conditions that affect the eyes and vision. These therapies aim to alleviate symptoms, slow down disease progression, or, in some cases, restore visual function. There are numerous ophthalmic diseases, each requiring specific therapeutic approaches. Therapies for ophthalmic diseases are continually evolving with advances in medical research and technology. It's essential for individuals with eye conditions to receive proper diagnosis and management from eye care professionals, such as ophthalmologists or optometrists, to ensure appropriate treatment and preservation of vision.

Key Trends in the Ophthalmic Disease Therapeutics Market

Here are some key trends in the market:

  • Advancements in Targeted Therapies: Presently, there is a significant trend toward the development of targeted therapies for various ophthalmic diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy. These therapies aim to provide more effective and precise treatment options.
  • Rise in Gene Therapies: Gene therapies for inherited eye diseases are gaining prominence. Researchers and pharmaceutical companies are actively developing gene-based treatments to address genetic eye disorders, offering the potential for long-term benefits.
  • Teleophthalmology and Remote Monitoring: In the current landscape, teleophthalmology and remote monitoring technologies are becoming increasingly important for the early detection and management of eye diseases. These technologies improve access to eye care services, especially in underserved regions.
  • Focus on Dry Eye Therapies: Dry eye disease is a prevalent condition, and the market is currently witnessing a focus on innovative therapies, including novel formulations and drug delivery systems, to address this unmet medical need.
  • Personalized Medicine Approaches: Personalized medicine is gaining traction in ophthalmology. Tailoring treatments to an individual's genetic makeup and disease characteristics are becoming more common, leading to improved outcomes and patient satisfaction.

Ophthalmic Disease Therapeutics Market Segmentations

Market Breakup by Disease Type

  • Glaucoma
  • Dry Eye Disease
  • Retinal Disease
  • Allergy and Infections
  • Diabetic Retinopathy
  • Others

Market Breakup by Drug Class

  • Anti-inflammatory Drugs
  • Anti-infective Drugs
  • Anti-VEGF (Vascular Endothelial Growth Factor) Drugs
  • Anti-glaucoma Drugs
  • Corticosteroids
  • Others

Market Breakup by Route of Administration

  • Topical
  • Oral
  • Intravenous

Market Breakup by Dosages Form

  • Solid
  • Liquid
  • Semi- Solid

Market Breakup by Distribution Channel

  • Hospitals Pharmacies
  • Retail pharmacies
  • Online Pharmacies
  • Others

Market Breakup by End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Homecare Settings
  • Others

Market Breakup by Region- 7MM

  • United States
  • EU-4 and the United Kingdom
  • Japan

Ophthalmic Disease Therapeutics Market Scenario

  • Market Growth: Presently, the global ophthalmic disease therapeutics market is experiencing robust growth due to the increasing prevalence of eye diseases, including age-related conditions like AMD, and the rising demand for effective treatments.
  • Impact of Aging Population: The aging global population is a significant factor shaping the market. As the elderly population grows, the incidence of age-related eye diseases is also increasing, driving the demand for ophthalmic therapeutics.
  • Ongoing Clinical Trials: The market scenario is characterized by a multitude of ongoing clinical trials for new ophthalmic therapies. These trials focus on evaluating novel treatments for various eye disorders, promising continuous innovation.
  • Access to Eye Care Services: Presently, efforts are being made to improve access to eye care services, especially in developing regions. This is influencing market dynamics as more people seek treatment for eye conditions.
  • Evolving Regulatory Environment: Changes in the regulatory landscape for ophthalmic therapeutics are impacting market scenarios. Stringent regulations ensure the safety and efficacy of treatments while requiring rigorous testing and approval processes.

Ophthalmic Disease Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in the market are as follows:

  • Pfizer Inc.
  • Alcon
  • Novartis AG
  • Bausch Health Companies Inc.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc
  • Allergan
  • Bayer AG
  • Genentech, Inc.
  • Nicox
The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ophthalmic Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ophthalmic Disease Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2017-2032)
5.2 United States Ophthalmic Disease Epidemiology (2017-2032)
5.3 EU-4 and United Kingdom Ophthalmic Disease Epidemiology (2017-2032)
5.4 Japan Ophthalmic Disease Epidemiology (2017-2032)
6 Ophthalmic Disease Therapeutics Market Overview
6.1 Ophthalmic Disease Therapeutics Market Historical Value (2017-2023)
6.2 Ophthalmic Disease Therapeutics Market Forecast Value (2024-2032)
7 Ophthalmic Disease Therapeutics Market Landscape
7.1 Ophthalmic Disease Therapeutics Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ophthalmic Disease Therapeutics Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Ophthalmic Disease Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ophthalmic Disease Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ophthalmic Disease Therapeutics Market Segmentation
11.1 Ophthalmic Disease Therapeutics Market by Disease Type
11.1.1 Market Overview
11.1.2 Glaucoma
11.1.3 Dry Eye Disease
11.1.4 Retinal Disease
11.1.5 Allergy and Infections
11.1.6 Diabetic Retinopathy
11.1.7 Others
11.2 Ophthalmic Disease Therapeutics Market by Drug Class
11.2.1 Market Overview
11.2.2 Anti-inflammatory Drugs
11.2.3 Anti-infective Drugs
11.2.4 Anti-VEGF (Vascular Endothelial Growth Factor) Drugs
11.2.5 Anti-glaucoma Drugs
11.2.6 Corticosteroids
11.2.7 Others
11.3 Ophthalmic Disease Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Topical
11.3.3 Oral
11.3.4 Intravenous
11.4 Ophthalmic Disease Therapeutics Market by Dosages Form
11.4.1 Market Overview
11.4.2 Solid
11.4.3 Liquid
11.4.4 Semi- Solid
11.5 Ophthalmic Disease Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospitals Pharmacies
11.5.3 Retail pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Ophthalmic Disease Therapeutics Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Clinics
11.6.4 Ambulatory Surgical Centers
11.6.5 Homecare Settings
11.6.6 Others
11.7 Ophthalmic Disease Therapeutics Market by Region-7MM
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.4 Japan
12 United States Ophthalmic Disease Therapeutics Market
12.1 U.S. Ophthalmic Disease Therapeutics Market Historical Size (2017-2023)
12.2 U.S. Ophthalmic Disease Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Drug Class
13 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market
13.1 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Drug Class
14 Japan Ophthalmic Disease Therapeutics Market
14.1 Japan Ophthalmic Disease Therapeutics Market Historical Size (2017-2023)
14.2 Japan Ophthalmic Disease Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Drug Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisition
21.1.5 Certifications
21.2 Alcon
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisition
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisition
21.3.5 Certifications
21.4 Bausch Health Companies Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisition
21.4.5 Certifications
21.5 Merck & Co., Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisition
21.5.5 Certifications
21.6 Regeneron Pharmaceuticals Inc
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisition
21.6.5 Certifications
21.7 Allergan
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisition
21.7.5 Certifications
21.8 Bayer AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisition
21.8.5 Certifications
21.9 Genentech, Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisition
21.9.5 Certifications
21.10 Nicox
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisition
21.10.5 Certifications
22 Ophthalmic Disease Therapeutics Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket

Companies Mentioned

  • Pfizer Inc.
  • Alcon
  • Novartis AG
  • Bausch Health Companies Inc.
  • Merck & Co. Inc.
  • Regeneron Pharmaceuticals Inc
  • Allergan
  • Bayer AG
  • Genentech Inc.
  • Nicox